Mirati Therapeutics is developing treatment for patients with cancer by targeting the genetic changes in tumor cells that result in uncontrolled tumor growth and spread. Its precision oncology strategy seeks to treat the patients most likely to benefit and is driven by drugs that target very specific genetic mutations that cause cancer and genomic tests that identify patients who carry those driver mutations.

Genprex is a privately held, clinical-stage biopharmaceutical company developing nanovesicle therapies that control universal cancer pathways to unlock the unrealized potential of a variety of targeted cancer therapies. The company's pan-kinase inhibitors work to induce apoptosis (programmed cell death) in cancer cells and to control cell signaling and inflammatory pathways. These biologic therapies target key oncogenic pathways to treat tumors and cancer metastases at the molecular level without harming normal cells. Used in combination with other targeted therapies, these drugs overcome genomic limitations inherent with targeted therapies including tyrosine kinase inhibitory drugs (TKIs). Genprex technologies also can be used to reduce drug resistance in patients with intrinsic or acquired drug resistance. Its products will broadly participate in the global oncology marketplace by addressing the unmet medical needs of cancer patients and expanding populations of patients benefiting from our combination treatments.